Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

H. Banu

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

When bones hurt in many places: A diagnostic puzzle in a 13-year-old boy

Background: Severe nutritional Vitamin D deficiency leading to secondary hyperparathyroidism can clinically mimic or mask underlying genetic bone disease. A key challenge is distinguishing whether diffuse skeletal osteosclerosis represents a metabolic reaction to elevated parathyroid hormone (PTH) or a primary defect i...

Tahmina Rahman, T. Tofail, H. Banu et al. · 0 citations
Open access Oct 2026

When hypoglycemia unmasks malignancy: A metastatic insulinoma presenting with recurrent hypoglycemia

Background: Spontaneous hypoglycemia in non-diabetic adults is an uncommon clinical entity. Endogenous hyperinsulinism caused by a metastatic pancreatic neuroendocrine tumor (malignant insulinoma) represents a rare and critical diagnosis requiring prompt identification and medical stabilization when surgical cure is pr...

Mariam Sultana, Zarin Tasnim Siddiqua, Nur Nahar Begom et al. · 0 citations
Open access Oct 2026

Beyond the textbook phenotype: Debunking myths in pseudohypoparathyroidism

Background: Pseudohypoparathyroidism type 1A (PHP1A), now classified within the spectrum of inactivating PTH/PTHrP signaling disorders (iPPSD), is often recognized by the stereotypical Albright hereditary osteodystrophy (AHO) phenotype and parathyroid hormone (PTH) resistance. However, subtle or atypical phenotypic exp...

Abdullah Al Noman Bhuiyan, Nur-E-Haseen Prodhan, Fahmida Akther et al. · 0 citations
Open access Oct 2026

Efficacy of low-dose semaglutide added to metformin on clinical and metabolic parameters in women with polyendocrine metabolic ovarian syndrome and obesity: A phase II randomized controlled trial

Background: Obesity exacerbates metabolic and androgenic abnormalities in polycystic ovary syndrome (PCOS). Although metformin is widely used, its effects on weight and metabolic dysfunction are modest. Semaglutide may offer additional benefit, but evidence in South Asian women with PCOS and obesity is limited. Objecti...

Md. Rafayel Islam, Md Shahed-Morshed, H. Banu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.